Comparison of recovery profiles in patients with Parkinson's disease for 2 types of neuromuscular blockade reversal agent following deep brain stimulator implantation

As an anesthetic reversal agent, there are concerns with cholinesterase inhibitors regarding worsening of Parkinson's disease (PD)-related symptoms. Sugammadex, a relatively new reversal agent, does not inhibit acetylcholinesterase and does not require co-administration of an antimuscarinic age...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yong-Seok, Kim, Jaewon, Kim, Sung-Hoon, Moon, Young-Jin, Kwon, Hye-Mee, Park, Hee-Sun, Kim, Wook-Jong, Ha, Seungil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
3300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946526/
https://www.ncbi.nlm.nih.gov/pubmed/31876713
http://dx.doi.org/10.1097/MD.0000000000018406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946526/
https://www.ncbi.nlm.nih.gov/pubmed/31876713
http://dx.doi.org/10.1097/MD.0000000000018406

Ejemplares similares